Leerink analyst Andrew Berens raised the firm’s price target on Zymeworks (ZYME) to $37 from $24 and keeps an Outperform rating on the shares after the company reported that Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival versus the control arm in the HERIZON-GEA-01 study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks’ Promising Clinical Trial Results and Market Potential Justify Buy Rating
- Zymeworks price target raised to $35 from $22 at Citi
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
- Zymeworks Announces Positive Phase 3 Trial Results